Clave Capital and BHH collaborate to accelerate investment in technology transfer projects in Healthcare

FEBRUARY 21, 2022 BHH News

Clave Capital, the Navarra-headquartered alternative asset investment manager, has announced a collaboration agreement with Barcelona Health Hub, one of the leading digital health hubs in Europe. It aims to accelerate investment and development of technology transfer projects in the healthcare sector, as well as cooperating in the transfer of knowledge between the different agents in the healthcare ecosystem. This alliance with Barcelona Health Hub, a leading institution that promotes knowledge, dissemination and innovation in digital health, demonstrates Clave Capital's commitment to promote advances in the healthcare industry through the participation, development and execution of the different training and dissemination activities promoted by the hub. The private capital firm will contribute with its extensive expertise in the field of healthcare research and technology transfer to establish synergies with the various leading players in the sector and boost the research and development ecosystem in Spain. Partnership with CDTI for technology transfer projects In early February, Clave Capital announced the launch of a fund with a target size of 80 million euros to invest in early-stage technology transfer projects linked to knowledge-generating centers in the healthcare field. This vehicle received a 40 million euros commitment from the Spanish State-backed Center for the Development of Industrial Technology (CDTI), via its programme Innvierte, following a competitive selection process in which 11 fund managers participated. Its aim is to be the reference in healthcare technology transfer in Spain, investing in profitable projects in disruptive sectors (medtech, ehealth, health & nutrition) and promoting the capitalization of Spanish Innovative Technology-Based Companies built on the knowledge generated in Research and Technology Centers. Clave Capital has wide experience in this field and up to 44% of the current tech transfer funds are destined to Healthtech, where it currently has a portfolio of 17 investees which have seen a significant market growth. In addition, in the past it invested in 4 other companies in the industry, such as Cytognos, focused on clinical flow cytometry solutions; Gadea, an independent Spanish pharmaceutical group dedicated to the development, production and commercialization of Active Pharmaceutical Ingredients; or 3P, a global CDMO specialized in the development and GMP manufacturing of biopharmaceutical and cell therapy products; all 3 of them obtaining returns of more than 2 times the investment.

You may also like

See all